MedPath

Effect of Organic Naked Oat With Whole Germ on Type 2 Diabetes Mellitus

Not Applicable
Completed
Conditions
Diabetes Mellitus
Interventions
Dietary Supplement: organic naked oat with whole germ (ONOG)
Registration Number
NCT01495052
Lead Sponsor
Yong Li
Brief Summary

Dietary modification is of great essential for the prevention and treatment of type 2 diabetes mellitus. Common oat (Avena sativa L.) and its products showed a great potential benefits on NCDs including type 2 diabetes mellitus. But data about such effects of naked oat (Avena nuda L.) is still unavailable. The investigators aimed to examine the effects of organic naked oat with whole germ (ONOG) plus diet on patients with type 2 diabetes.

After a pre-study with healthy adults, a randomized, single-blinded, multi-arm parallel trial of 30 days would be carried out in adults of 50-65 years old with type 2 diabetes. Participants would be randomly assigned to one of the four following groups: usual care group (only basic health advice, no other interventions), diet group (systematic education, structured dietary), 50g-ONOG plus diet group (all the interventions of diet group plus replacement of 50g ONOG per day) and 100g-ONOG plus diet group. A regular follow-up for years would be carried out to predict the long-term effects of ONOG plus diet intervention on patients with type 2 diabetes.

The investigators hypothesized that ONOG combined with diet would have better effects on glycaemia and insulin resistance control in addition to those yielded by diet or usual care.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
445
Inclusion Criteria
  • all adults aged 50-65 years old with Type 2 Diabetes Mellitus
  • stable physical condition
  • fasting plasma glucose (FPG) concentration ≥7.8mmol/L or 2-h postprandial blood glucose (PG) ≥11.1mmol/L after 75g oral dextrose with an glycated hemoglobin (HbA1c)>7 %, stable medication.
Exclusion Criteria
  • pregnancy
  • breastfeeding
  • severe renal or hepatic complications
  • treatment by glucocorticoid
  • having pancreatic disease or malignancy in recent 3 months
  • other factors that may limit adherence to interventions or affect conduct of the trial or participation in another supplementary feeding programme.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
50g-ONOG plus diet grouporganic naked oat with whole germ (ONOG)This group received systematic education about nutrition and diabetes combined with a structured dietary intervention. Participants in the 50g-ONOG plus diet groups were asked to replace their customarily used staple food with oat porridge containing 50g ONOG.
100g-ONOG plus diet grouporganic naked oat with whole germ (ONOG)This group received systematic education about nutrition and diabetes combined with a structured dietary intervention. Participants in the 100g-ONOG plus diet groups were asked to replace their customarily used staple food with oat porridge containing 100g ONOG.
Primary Outcome Measures
NameTimeMethod
change from baseline in Hb1Ac concentration Hematology index detection Hematology index detection Hematology index detection Hematology index detection Hematology index detectionbaseline, 30 days, 6 months and 1 year

Venous blood samples were collected for determination of glycosylated haemoglobin (HbA1c).Changes in outcomes were calculated as values at the end of the intervention period minus those of baseline.

changes from baseline in insulin resistance Hematology index detection Hematology index detection Hematology index detection Hematology index detection Hematology index detectionbaseline, 30 days, 6 months and 1 year

Venous blood samples were collected for determination of serum insulin.Insulin resistance was measured by HOMO-IR, calculated with the following formula:

HOMO-IR=Fasting serum insulin(μU/mL)\*FPG(mmol/L)/22.5

Secondary Outcome Measures
NameTimeMethod
changs from baseline in plasma glucosebaseline, 30 days, 6 months and 1 year

Venous blood samples were collected for determination of fasting plasma glucose(FPG), postprandial blood glucose (PG).Changes in outcomes were calculated as values at the end of the intervention period minus those of baseline.

changes from baseline in lipid profilebaseline, 30 days, 6 months and 1 year

Venous blood samples were collected for determination of total triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c). Changes in outcomes were calculated as values at the end of the intervention period minus those of baseline.

changes from baseline in BMIbaseline, 30 days, 6 months and 1 year

Weight and height were measured at each time. BMI was calculated as weight divided by square height.Changes in outcomes were calculated as values at the end of the intervention period minus those of baseline.

changes from baseline in plasma levels of total glutathione peroxidase, malondialdehyde(MDA), superoxide dismutase (SOD), IL-6 and TNF-аbaseline and 30 days

Venous blood samples were collected for determination of total glutathione peroxidase, malondialdehyde(MDA), superoxide dismutase (SOD), IL-6 and TNF-а. Changes in outcomes were calculated as values at the end of the intervention period minus those of baseline.

changes from baseline in WHRbaseline, 30 days, 6 months and 1 year

waist circumference and hip circumference were measured at each time. WHR was calculated as waist circumference divided by hip circumference.Changes in outcomes were calculated as values at the end of the intervention period minus those of baseline.

Trial Locations

Locations (1)

Arms Industry New Century Hotel

🇨🇳

Baotou, Inner Mongolia Autonomous Region, China

© Copyright 2025. All Rights Reserved by MedPath